Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001323 | 0.82 | ALDH1A1 (0.47) | HRH3HDAC6FBP1ALDH1A1 | |
| SCHEMBL3590995 | 0.82 | CES1 (0.38) | HRH3HDAC6FBP1ALDH1A1KLKB1 | |
| SCHEMBL1166830 | 0.82 | FPR2 (0.42) | FPR2DAGLAFPR3HRH3HDAC6 | |
| SCHEMBL19871354 | 0.82 | FPR2 (0.40) | FPR2DAGLAFPR3HRH3HDAC6 | |
| SCHEMBL1706523 | 0.79 | DAGLA (0.40) | FPR2DAGLAFPR3HRH3HDAC6 | |
| SCHEMBL14076074 | 0.78 | FPR2 (0.45) | FPR2DAGLAFPR3HRH3HDAC6 | |
| SCHEMBL25014083 | 0.76 | FBP1 (0.36) | FBP1ALDH1A1 | |
| SCHEMBL16259514 | 0.74 | NOTUM (0.32) | — | |
| SCHEMBL16259527 | 0.74 | — | — | |
| SCHEMBL21333174 | 0.74 | DAGLA (0.52) | FPR2DAGLAKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012077051-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | ADORA1, ADORA3, HCAR3 | FPR2 333/4885DAGLA 4565/4885FPR3 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.